Upgrade to SI Premium - Free Trial

Truist Securities Reiterates Buy Rating on Regeneron Pharma (REGN) After Eylea Deemed Inapplicable for MFN Rule

January 4, 2021 7:46 AM
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $770.00 price target on Regeneron Pharma (NASDAQ: REGN) after the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments